Novo Nordisk’s Two-Stage Catalyst: Earnings Due August 5 as CagriSema FDA Verdict Hovers
Novo Nordisk is entering a defining stretch of the year, with two pivotal events that could reshape the…
Novo Nordisk’s Oral GLP-1 Assault Begins as Earnings Cloud Hovers Over the Stock
Novo Nordisk rolls out oral semaglutide for diabetes and weight loss as Q1 earnings loom, with stock down…